Lisa Taylor-Swanson, PhD, on a pilot in which integrative group medical visits improved menopause symptoms, knowledge, and self-efficacy.
|Articles|May 30, 2022
This week on Contemporary OBGYN®: May 31 to June 3
Author(s)Lindsey Carr, Editor
Find out what's happening in women's health this week.
Advertisement
The world of the pediatric adolescent patient
In the June issue of Contemporary OB/GYN®, we focus on pediatric and adolescent gynecology. Dr. Spong's editorial outlines the articles featured in this month's issue and highlights the importance of different perspectives.
Managing genital and pelvic pain in young patients
Part 2 in a series on emergencies in pediatric and adolescent gynecology.
Providing the best care for transgender adolescents
Offering an inclusive, safe space along with the best care for transgender and nonbinary adolescent patients is more important than ever.
How to identify common pediatric vulvar conditions
Understanding signs and symptoms helps determine the best treatment regimen.
Advertisement
Related to this article
Peter Hsin, BS, discusses a meta-analysis linking perioperative ketamine to lower early postpartum depressive symptoms after cesarean delivery.
A recap of the top video interviews from Contemporary OB/GYN's coverage of The Menopause Society 2026 Annual Meeting in San Diego.
Susan Reed, MD, MPH, MS, and Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, weigh in on FDA boxed warning removals for menopausal hormone therapy.
The FDA granted accelerated approval to Voceryq to reduce papilloma excision surgeries in adults with recurrent respiratory papillomatosis.
A recap of the top women's health headlines from October 2026, including FDA approval of pritelivir for refractory HSV, ACOG's new menopause guideline, and more.
Chrisandra Shufelt, MD, on using a cardiovascular risk score to guide hormone therapy candidacy at menopause.
The October 30 update from the FDA follows the February 12, 2026 labeling changes to 6 menopausal hormone therapy products in which the agency also removed safety-related boxed warnings.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Choosing Among Hormonal and Nonhormonal VMS Therapies in Menopause
2
FDA removes boxed warnings from 3 more menopausal hormone therapy products
3
Top video interviews from The Menopause Society 2026 Annual Meeting
4
Top headlines in women's health from October 2026
5